Emactuzumab (Anti-CSF1R / M-CSFR / CD115)

製品コードA2851 別名: RG 7155; RO 5509554 純度：99%

Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 58200	国内在庫あり
1mg*5	JPY 144600	お問い合わせ
1mg*25	JPY 432600	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る： A285101 純度： 99% タンパク質濃度： 19.01mg/ml 内毒素：＜1EU/mg

TAM receptors (Tyro-3,Axl,and Mertk)阻害剤の選択性比較

生物活性

製品説明	Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD.

参考
https://pubmed.ncbi.nlm.nih.gov/26179200/

参考

https://pubmed.ncbi.nlm.nih.gov/26179200/

製品説明

CAS No.	1448221-67-7
Molecular Weight	146.94
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03768063	ACTIVE_NOT_RECRUITING	Drug: Atezolizumab\|Drug: Bevacizumab\|Drug: Alectinib\|Drug: C	Cancer	Hoffmann-La Roche	2019-02-28	PHASE3
NCT05417789	ACTIVE_NOT_RECRUITING	Drug: Emactuzumab\|Drug: Placebo	TGCT	SynOx Therapeutics Limited	2024-10-09	PHASE3
NCT02923739	TERMINATED	Drug: Paclitaxel	Fallopian Tube Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma	M.D. Anderson Cancer Center	2017-05-05	PHASE2
NCT02323191	COMPLETED	Drug: Atezolizumab\|Drug: Emactuzumab	Solid Cancers	Hoffmann-La Roche	2015-01-19	PHASE1
NCT02471716	COMPLETED		Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor	Five Prime Therapeutics, Inc.	2015-06	PHASE1; PHASE2
NCT03369964	WITHDRAWN	Drug: Atezolizumab\|Drug: Emactuzumab\|Drug: Obinutuzumab	Lymphoma, Non-Hodgkin	Hoffmann-La Roche	2018-03-14	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-24)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須